A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
Clinical trial NCT05665595 · TERMINATED
Trial details
- NCT number
- NCT05665595
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-19
- Primary completion
- 2024-03-06
- Enrollment
- 1594
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.